▶ 調査レポート

3Dバイオプリンティングのグローバル市場(~2027):インクジェット3Dバイオプリンティング、レーザーアシストバイオプリンティング、磁気3Dバイオプリンティング、マイクロ押出バイオプリンティング

• 英文タイトル:3D Bioprinting Market Research Report by Technology, Material, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

3D Bioprinting Market Research Report by Technology, Material, Application, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「3Dバイオプリンティングのグローバル市場(~2027):インクジェット3Dバイオプリンティング、レーザーアシストバイオプリンティング、磁気3Dバイオプリンティング、マイクロ押出バイオプリンティング」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2305D090
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、254ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:材料
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥732,452 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,472,452 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社は、世界の3Dバイオプリンティング市場規模が2021年に1,194.05百万ドル、2022年には1,446.00百万ドルに達し、更に年平均21.27%成長して2027年には3,799.19百万ドルまで拡大すると予測しています。当調査資料は、3Dバイオプリンティングの世界市場についての多面的な調査を元に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別分析(インクジェット3Dバイオプリンティング、レーザーアシストバイオプリンティング、磁気3Dバイオプリンティング、マイクロ押出バイオプリンティング)、材料別分析(細胞外マトリックス、ヒドロゲル、生存細胞)、用途別分析(臨床、研究)、エンドユーザー別分析(製薬&バイオテクノロジー企業、研究機関)、地域別分析(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)、競争状況、企業情報などの構成でまとめております。また、当書には、3 Dynamics Systems Ltd.、Advanced Solutions Life Sciences, LLC、Allevi、Arcam AB、Cellink AB、Cyfuse Biomedical K.K.、Digilab, Inc.、EnvisionTEC GmbH、FUJIFILM Wako Automation Corporation、GeSiM mbH、Inventia Life Science PTY LTDなどの企業情報が含まれています。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界の3Dバイオプリンティング市場規模:技術別
- インクジェット3Dバイオプリンティングの市場規模
- レーザーアシストバイオプリンティングの市場規模
- 磁気3Dバイオプリンティングの市場規模
- マイクロ押出バイオプリンティングの市場規模
・世界の3Dバイオプリンティング市場規模:材料別
- 細胞外マトリックスの市場規模
- ヒドロゲルの市場規模
- 生存細胞の市場規模
・世界の3Dバイオプリンティング市場規模:用途別
- 臨床における市場規模
- 研究における市場規模
・世界の3Dバイオプリンティング市場規模:エンドユーザー別
- 製薬&バイオテクノロジー企業における市場規模
- 研究機関における市場規模
・世界の3Dバイオプリンティング市場規模:地域別
- 南北アメリカの3Dバイオプリンティング市場規模
アメリカの3Dバイオプリンティング市場規模
カナダの3Dバイオプリンティング市場規模
ブラジルの3Dバイオプリンティング市場規模
...
- アジア太平洋の3Dバイオプリンティング市場規模
日本の3Dバイオプリンティング市場規模
中国の3Dバイオプリンティング市場規模
インドの3Dバイオプリンティング市場規模
韓国の3Dバイオプリンティング市場規模
台湾の3Dバイオプリンティング市場規模
...
- ヨーロッパ/中東/アフリカの3Dバイオプリンティング市場規模
イギリスの3Dバイオプリンティング市場規模
ドイツの3Dバイオプリンティング市場規模
フランスの3Dバイオプリンティング市場規模
ロシアの3Dバイオプリンティング市場規模
...
- その他地域の3Dバイオプリンティング市場規模
・競争状況
・企業情報

The Global 3D Bioprinting Market size was estimated at USD 1,194.05 million in 2021 and expected to reach USD 1,446.00 million in 2022, and is projected to grow at a CAGR 21.27% to reach USD 3,799.19 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the 3D Bioprinting to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Technology, the market was studied across Inkjet 3D Bioprinting, Laser-assisted Bioprinting, Magnetic 3D Bioprinting, and Microextrusion Bioprinting.

Based on Material, the market was studied across Extracellular Matrices, Hydrogels, and Living Cells.

Based on Application, the market was studied across Clinical Applications and Research Applications.

Based on End User, the market was studied across Pharmaceutical & Biotechnology Companies and Research Organizations.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for 3D Bioprinting market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the 3D Bioprinting Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global 3D Bioprinting Market, including 3 Dynamics Systems Ltd., Advanced Solutions Life Sciences, LLC, Allevi, Arcam AB, Cellink AB, Cyfuse Biomedical K.K., Digilab, Inc., EnvisionTEC GmbH, FUJIFILM Wako Automation Corporation, GeSiM mbH, Inventia Life Science PTY LTD, Luxexcel Group B.V., Nano3D Biosciences, Inc., Organovo Holdings Inc, Poietis, Regemat 3D S.L., RegenHU SA, Regenovo Biotechnology Co., Ltd., ROKIT Healthcare, INC., Stratasys Ltd, TeVido BioDevices, Inc, and Vivax Bio, LLC.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global 3D Bioprinting Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global 3D Bioprinting Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global 3D Bioprinting Market?
4. What is the competitive strategic window for opportunities in the Global 3D Bioprinting Market?
5. What are the technology trends and regulatory frameworks in the Global 3D Bioprinting Market?
6. What is the market share of the leading vendors in the Global 3D Bioprinting Market?
7. What modes and strategic moves are considered suitable for entering the Global 3D Bioprinting Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising demand from pharmaceutical and cosmetology sector
5.1.1.2. Proliferation in advancements of 3D bioprinters and biomaterials
5.1.1.3. Increasing aging population coupled with limited number of organ donors
5.1.2. Restraints
5.1.2.1. Scarcity of 3D cell-based infrastructure
5.1.3. Opportunities
5.1.3.1. Increasing research funding provided for doctoral academic projects
5.1.3.2. Implementation of 3D cell culture as a better alternative to animal testing
5.1.4. Challenges
5.1.4.1. Capital intensive to perform cell biology research
5.2. Cumulative Impact of COVID-19

6. 3D Bioprinting Market, by Technology
6.1. Introduction
6.2. Inkjet 3D Bioprinting
6.3. Laser-assisted Bioprinting
6.4. Magnetic 3D Bioprinting
6.5. Microextrusion Bioprinting

7. 3D Bioprinting Market, by Material
7.1. Introduction
7.2. Extracellular Matrices
7.3. Hydrogels
7.4. Living Cells

8. 3D Bioprinting Market, by Application
8.1. Introduction
8.2. Clinical Applications
8.3. Research Applications

9. 3D Bioprinting Market, by End User
9.1. Introduction
9.2. Pharmaceutical & Biotechnology Companies
9.3. Research Organizations

10. Americas 3D Bioprinting Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific 3D Bioprinting Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa 3D Bioprinting Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. 3 Dynamics Systems Ltd.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Advanced Solutions Life Sciences, LLC
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Allevi
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Arcam AB
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Cellink AB
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Cyfuse Biomedical K.K.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Digilab, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. EnvisionTEC GmbH
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. FUJIFILM Wako Automation Corporation
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. GeSiM mbH
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Inventia Life Science PTY LTD
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Luxexcel Group B.V.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Nano3D Biosciences, Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Organovo Holdings Inc
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Poietis
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Regemat 3D S.L.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. RegenHU SA
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Regenovo Biotechnology Co., Ltd.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. ROKIT Healthcare, INC.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Stratasys Ltd
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. TeVido BioDevices, Inc
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Vivax Bio, LLC
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing